Ones To Watch News
Refine Search
Biotechnology
French manufacturer Sartorius Stedim Biotech and Nanotein Technologies, a developer of next-generation immune cell activation reagents, have entered into a partnership. 11 August 2025
Biotechnology
Denmark-based IO Biotech’s shares traded 51% higher ahead of the morning bell at $2.74 after the company said that Cylembio (imsapepimut and etimupepimut 11 August 2025
Biotechnology
The US Food and Drug Administration (FDA) has ordered label changes for bluebird bio's Skysona (elivaldogene autotemcel) due to blood cancer risks associated with the gene therapy product. 11 August 2025
Biotechnology
Indian cell therapy company Eyestem Research has raised $10 million in a significantly oversubscribed funding round to support the next stage of development for its investigational retinal pigment epithelial (RPE) cell therapy, Eyecyte-RPE. 11 August 2025
Biotechnology
US clinical-stage biotech Vor Bio has announced the appointment of Dallan Murray as chief commercial officer, effective immediately. 11 August 2025
Pharmaceutical
USA-based biotech DoveTree Medicines has signed a far-reaching partnership with Chinese drug discovery company XtalPi, in a deal worth up to $5.99 billion. 7 August 2025
Biotechnology
US artificial intelligence drug discovery firm Chai Discovery has secured $70 million in Series A funding, drawing backing from several high-profile investors as it seeks to transform how new biologic drugs are engineered. 7 August 2025
Biotechnology
Shattuck Labs yesterday announced that it has entered into a securities purchase agreement for a private placement financing 6 August 2025
Biotechnology
US cardiometabolic specialist MetaVia has announced a research collaboration with Korea’s Syntekabio, an artificial intelligence (AI)-driven drug discovery company. 5 August 2025
Biotechnology
XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday. 5 August 2025
Biotechnology
Texas, USA-based Nanoscope Therapeutics has recently submitted a rolling biologics license application (BLA) to the Food and Drug Administration (FDA) for MCO-010 (sonpiretigene isteparvovec), a novel gene therapy candidate targeting retinitis pigmentosa (RP). 5 August 2025
Biotechnology
Privately-held US clinical-stage biotech Cellergy Pharma announced the appointment Christopher Cano as chief executive (CEO). 5 August 2025
Biotechnology
Swedish biotech Hansa Biopharma on Friday released encouraging top-line results from three patients with Duchenne muscular dystrophy (DMD) treated with Hansa’s imlifidase prior to receiving Sarepta Therapeutics’ Elevidys (delandistrogene moxeparvovec-rokl) in the SRP-9001-104 trial. 4 August 2025
Biotechnology
Germany’s BioNTech has reported revenues for the second quarter 2025 of 260.8 million euros ($302 million), more than double the 128.7 million euros of the same period in 2024 and way above the consensus estimate of €137.9 million euros. 4 August 2025
Biotechnology
Philadelphia, USA-based Medicus Pharma and Boston-based biotech Helix Nanotechnologies have entered into a non-binding memorandum of understanding (MoU) in respect of their shared mutual interest in the development of thermostable infectious diseases vaccines. 4 August 2025
Biotechnology
Allogene Therapeutics, a US biotech developing allogeneic CAR T products for cancer and autoimmune disease, closed 12% lower Friday after providing a key trial update. 4 August 2025
Biotechnology
Chinese biotech Mabgeek Biotechnology has filed to go public in Hong Kong, seeking to raise funds to support development of its pipeline of long-acting antibody therapies. The company, founded in 2016 and based in Hunan province, lists China International Capital Corporation as the sole sponsor. 4 August 2025
Pharmaceutical
Chinese biotech TenNor Therapeutics has filed to list on the main board of the Hong Kong Stock Exchange, aiming to fund late-stage development and commercialization of its pipeline of new antibacterial treatments. The Suzhou-based company is seeking to go public under Chapter 18A, a pathway for pre-revenue drugmakers. 4 August 2025
Pharmaceutical
New York-based Spine BioPharma on Friday revealed disappointing results with its growth factor beta (TGF-β) antagonist, SB-01 (vicateride). 4 August 2025
Biotechnology
US biopharma Viridian Therapeutics has entered into an exclusive collaboration and license agreement with Japanese firm Kissei Pharmaceutical to develop and commercialize veligrotug and VRDN-003 in Japan. 30 July 2025
Pharmaceutical
US privately-held drug developer NImmune Biopharma has acquired development and commercialization rights for omilancor in Asia from Sino-American biotech LianBio. 25 October 2024
Biotechnology
US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research collaboration with Roche to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. 24 October 2024
Biotechnology
Shares of Californian clinical-stage biotech Alto Neuroscience plummeted 70% to $4.36 yesterday, as is announced disappointing trial results for depression candidate. 24 October 2024
Pharmaceutical
Alpha-9 Oncology, a Canadian radiopharmaceutical company, has raised $175 million in an oversubscribed series C financing round led by Lightspeed Venture Partners and Ascenta Capital. 24 October 2024
Pharmaceutical
Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca, which is being triggered by successfully achieving milestones related to the development of ECC5004/AZD5004 including the first patient dosed in the Phase IIb program. 24 October 2024
Biotechnology
Ocuphire Pharma has announced its acquisition of Opus Genetics, a clinical-stage gene therapy company focused on treating inherited retinal diseases. 24 October 2024
Biotechnology
Editas Medicine has announced plans to seek a partner or buyer for its lead CRISPR program, reni-cel, as the company continues to shift its strategy. 23 October 2024
Biotechnology
France-based clinical-stage biotech Duhn Therapeutics (which is co-founded by Landmark BioVentures) and Swiss firm OM Pharma announced an exclusive license agreement to advance a pipeline of lipid-based cancer immunotherapies. 23 October 2024
Biotechnology
US clinical-stage biotech AvenCell Therapeutics announced that it has raised $112 million in Series B financing, which was led by global life sciences investor Novo Holdings. 23 October 2024
Biotechnology
Shares in Sangamo Therapeutics surged around 40% on Tuesday, following the announcement that the US Food and Drug Administration has granted the company a faster path to approval for its gene therapy ST-920 (isaralgagene civaparvovec) for Fabry disease. 23 October 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
Berlin, Germany-based Ariceum Therapeutics has presented data at the European Association of Nuclear Medicine 2024 conference on its first-in-class radiopharmaceutical drug, 225Ac-satoreotide. 22 October 2024
Pharmaceutical
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Biotechnology
Boston, USA-based Seaport Therapeutics has announced the closing of an oversubscribed $225 million Series B financing round, adding to the $100 million it pulled in along with its launch in April. 21 October 2024
Pharmaceutical
Sweden-based OncoZenge has announced the intention to partner with UK-based specialty pharma Pharmanovia to secure exclusive rights to commercialize BupiZenge in Europe, the Middle East, and Northern Africa (EMENA). 21 October 2024
Pharmaceutical
Angelini Pharma, part of Italy’s Angelini Industries, has entered into an exclusive option agreement with South Korea-based Cureverse for the global development and commercialization of a clinical-stage brain health asset. 21 October 2024
Biotechnology
LaNova Medicines, a Shanghai-based biopharma company, has announced that it has secured 3 billion yuan ($41 million) in its series C funding round. 18 October 2024
Biotechnology
Taiwan-based REGiMMUNE, a biopharma creating immunotherapies through the power of regulatory T cells (Tregs), and France-based Kiji Therapeutics, a specialist in induced pluripotent stem cells-mesenchymal stem cells (IPSC-MSC) engineered cell therapies for inflammatory diseases, are to merge. 18 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze